Sangui BioTech International, Inc. (SGBI: OTCQB) | Sangui BioTech: Laboratorios Silanes Start Marketing Granulox in Mexico


Sangui BioTech: Laboratorios Silanes Start Marketing Granulox in Mexico

Nov 03, 2014

OTC Disclosure News Service

Laboratorios Silanes (
commenced with the marketing of the dressing material Granulox in Mexico
on November 1, 2014, based on an exclusive agreement with SastoMed GmbH.
At the same time, Silanes has taken over the distribution for the
remaining countries of Central America and is currently applying for the
necessary certifications in the respective individual markets. To be
ready for the start of distribution, Silanes ordered, received and paid
for merchandise in the previous quarter, which was reflected in a
considerable five-digit license income by Sangui as of 30 September 2014.

Laboratorios Silanes was founded in 1943 and, with a workforce of around
700 employees, today ranks among the leading mid-sized pharmaceutical
companies of Central America and in terms of revenues occupies third
place in the league of the highest-volume suppliers of products suitable
for diabetics.

Prior to the start of the distribution, 250 sales representatives took
part in a training event which also included an in-depth presentation by
Michael Sander, Chief Executive Officer of SastoMed GmbH, the global
licensee for the sale of Granulox. The sales force was introduced to the
mode of action and the application in a series of detailed scientific
and practical presentations, and given the marketing goals and materials.

“The start to marketing by Silanes concludes intensive preliminary work
which took two years and the restructuring of our Mexico business”,
explained Michael Sander. “Thanks to the support of BioMac CEO John
McArdle, we now have gained a highly professional partner in Silanes
which has the market position to leverage the public profile of Granulox
locally and to translate it into tangible success.”

Antonio Lopez de Silanes, jr., the owner of Laboratorios Silanes,
explained at a national sales congress organized by his company that
Granulox had the potential for developing into a core component of the
product portfolio. He anticipates that the investments in pre-marketing
and marketing will soon pay off.

Sangui BioTech International, Inc. (“SGBI”) is a holding company the
shares of which are being traded on the OTCQB marketplace (
SGBI) and the OTC markets of Berlin and Hamburg-Hannover stock
exchanges. Its purpose is to provide financing and access to the capital
markets for the enterprises of the Sangui group. SanguiBioTech GmbH is a
ninety percent subsidiary of Sangui BioTech International, Inc.

Copyright © 2014 Businesswire. All Rights Reserved

The above news release has been provided by the above company via the OTC Disclosure and News Service. Issuers of news releases and not OTC Markets Group Inc. are solely responsible for the accuracy of such news releases.

Leave a Reply